A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT07323732
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Interstitial Lung Disease
- Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
- NSCLC
- NSCLC Stage II
- NSCLC, Stage I
- Non Small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage I
- Non-small Cell Lung Cancer Stage II
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BIO 300 — DRUGThe drug product, BIO 300 consists of synthetic genistein
Study Details
The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).
Key Dates
- Start date
- Jan 6, 2026
- Status verified
- Mar 2026
- Primary completion
- Jan 6, 2029
- Completion
- Jan 6, 2029
Study Design
- Enrollment
- 25 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Participants with Non-Small Cell Lung Cancer and Interstitial Lung DiseaseParticipants with Non-Small Cell Lung Cancer/NCSLC and Interstitial Lung Disease/ILD
Primary Outcome Measure
Pneumonitis free survival [ Time Frame: Up to 36 months ]
Central Contacts
- Narek Shaverdian, MD631-212-6323
- Jamie Chaft, MD646-608-3761
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | Narek Shaverdian, MD 631-212-6323 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | Narek Shaverdian, MD 631-212-6323 |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | Narek Shaverdian, MD 631-212-6323 |
| Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack | New York | 11725 | Narek Shaverdian, MD 631-212-6323 |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | Narek Shaverdian, MD 631-212-6323 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York | 10065 | Narek Shaverdian, MD 631-212-6323 |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 | Narek Shaverdian, MD 631-212-6323 |
Find similar trials in Basking Ridge, NJ
By condition
By specialty
By research site
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY
Related Studies
- WTC Chest CT Imaging ArchiveEnrolling By Invitation · Icahn School of Medicine at Mount Sinai · New York, New York
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseasePHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · San Carlos, California